Skip to main content

The 30-Year Fixed-Rate Mortgage Averages 6.46%

Primary Mortgage Market Survey®U.S. weekly average mortgage rates as of 04/02/2026MCLEAN, Va., April 02, 2026 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.46%. “The 30-year fixed-rate mortgage edged up, averaging 6.46% this week,” said Sam Khater, Freddie Mac’s Chief Economist. “With spring homebuying season in full swing, aspiring buyers should remember to shop around for the best mortgage rate, as they can potentially save thousands of dollars by getting multiple quotes.” News FactsThe 30-year FRM averaged 6.46% as of April 2, 2026, up from last week when it averaged 6.38%. A year ago at this time, the 30-year FRM averaged 6.64%. The 15-year FRM averaged 5.77%, up from last week when it...

Continue reading

Exosens secures record order for interceptor drone-based digital imaging solutions from major autonomous air defense systems developer

EXOSENS SECURES RECORD ORDER FOR INTERCEPTOR DRONE-BASED DIGITAL IMAGING SOLUTIONS FROM MAJOR AUTONOMOUS AIR DEFENSE SYSTEMS DEVELOPERLargest order to date for the supply of several thousand Exosens ultra-compact thermal camera cores, placed by a major European autonomous air defense systems developer This landmark order underscores the strength of Exosens’ digital imaging solutions for defense applications, particularly in the fast-growing drone and counter-drone space, increasingly central to modern defense operations Following this milestone, total orders secured over the past two quarters exceed 10,000 cameras across air, land, and sea unmanned platforms, establishing Exosens as a tier-one digital imaging partner among leading defense systems integrators in Europe, the U.S., and Asia Exosens’ ITAR-free digital imaging solutions equip...

Continue reading

RUBIS: Information relating to the total number of voting rights and shares as of 31/03/2026

 Paris, 2 April 2026, 5:45 pm    INFORMATION ON TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES PURSUANT TO ARTICLE L.233-8 II OF THE FRENCH COMMERCIAL CODE AND ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY   Date Class of shares Number of shares Number of theoretical voting rights Number of exercisable voting rights (excluding shares bought back by the Company (deprived of voting rights) and shares deprived of voting rights in accordance with art. L. 233-14 of the French Commercial Code)31 March 2026 Ordinary shares (par value of €1,25) 103,408,575 103,408,575 102,779,199  Contact  RUBIS – Legal department  Tel. : +33 (0)1 44 17 95 95AttachmentRUBIS: Information relating to the total number of voting rights and shares as of 31/03/2026

Continue reading

Nexity: Total number of voting rights and shares composing the share capital as of 31 March 2026

NEXITYSociété anonymeau capital de 280 648 620 eurosSiège Social : 67 rue Arago 93400 Saint-Ouen-sur-Seine444 346 795 RCS Bobigny Monthly disclosure of the total numberof voting rights and shares composing the share capital in accordance with Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés FinanciersInformation cut-off date Total numberof shares Net total number ofvoting rights31 March 2026   56,129,724   Total gross 56,129,724Net total 55,683,282* Net total = Total number of voting rights attached to the shares – shares without voting rights Saint-Ouen-sur-Seine, 2 April 2026Attachment2026_04_02 – Monthly disclosure of voting rights and shares – March 2026

Continue reading

Fnac Darty: Number of shares and voting rights as of March, 31 2026

Ivry-sur-Seine – France, April 2, 2026 Regulated information INFORMATION ON THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Statement in compliance with article L. 233-8 II of the French commercial code and article 223- 16 of the General Regulation of the French Financial Markets Authority (AMF – Autorité des marchés financiers)Stock Market Euronext ParisISIN Code FR0011476928Date   Total number of shares composing the share capital of the company Total number of gross voting rights   Total number of net voting rights (*)March 31, 2026 29,682,146 29,682,146 29,107,842(*) Net = After deduction of the shares deprived of voting right In accordance with Article 9 of the Company’s Articles of Association, any physical or legal person, acting alone or in concert, who comes to hold, or ceases to hold, directly or indirectly,...

Continue reading

DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 MARCH 2026

French public limited company (société anonyme)with a share capital of €1,455,643,262.50Registered office : 1973, boulevard de la Défense92000 Nanterre – France552 037 806 RCS Nanterrewww.vinci.com DISCLOSUREOF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 MARCH 2026Total number of shares 582,257,305Theoretical number of voting rights (including treasury stock) 582,257,305Number of voting rights (excluding treasury stock) 553,674,975This disclosure is on VINCI web site www.vinci.com(section: Finance/Investors/Regulatory information/7. Monthly information concerning the total number of voting rights and shares that make up the company’s capital)Attachment2026 03 31 ddv English version

Continue reading

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V. (“NEC”), a wholly owned subsidiary of NEC Corporation (TSE: 6701), a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer. TG4050 is an individualized immunotherapy based on an MVA viral vector incorporating neoantigens selected using NEC’s AI-enabled prediction platform. It is currently being evaluated in patients with head and neck cancer with the aim of preventing relapse and extending disease-free survival...

Continue reading

Michelin completes the acquisition of Flexitallic and accelerates growth in Polymer Composite Solutions

                                                                             Clermont-Ferrand, April 2nd, 2026 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Michelin completes the acquisition of Flexitallic and accelerates growth in Polymer Composite SolutionsMichelin completed the acquisition of Flexitallic, under the terms announced on February 3, 2026, and after obtaining all the necessary approvals for the transaction. Strong strategic fit, as both parties share the same commitment to innovation and high-quality products while operating worldwide, creating synergies for future growth. Acquisition financed through available cash, preserving Michelin’s strong financial position.Based in Houston, Texas, Flexitallic is a global leader in sealing solutions providing high-performance gaskets to critical sectors such as energy and...

Continue reading

SPIE signs an agreement for the acquisition of BLOCK Group in the Czech Republic

Cergy, April 2nd, 2026 – SPIE, the independent European leader in multi-technical services in the areas of energy and communications, announces the signing of an agreement for the acquisition of BLOCK Group, a Czech-based provider of cleanroom design, engineering, procurement and construction solutions. Founded in 1991, BLOCK Group is an experienced provider of turnkey cleanroom solutions and a well-established market leader in the Czech Republic. The Group supports clients operating in highly demanding sectors such as pharmaceuticals, biotechnology, healthcare, microelectronics and optics. BLOCK Group delivers comprehensive services across the full project lifecycle – from design and engineering through implementation to service and validation. Its area of expertise includes also process automation systems and high voltage installations....

Continue reading

AB KN Energies audited Annual information for the year 2025

AB KN Energies (hereinafter – KN, the Company) announces the audited consolidated (hereinafter – the Group) and separate financial results for the twelve months ended 31 December 2025. Key financial indicators for the 1-12 months of 2025:EUR millions Group Company  1-12 months of 2025 1-12 months of 2024 1-12 months of 2025 1-12 months of 2024Revenue 105.2 93.7 99.9 89.4EBITDA 53.5 48.8 51.2 46.4Normalized EBITDA 47.8 46.7 45.5 44.3Net profit (loss) 18.2 15.4 16.7 13.8Normalized net profit (loss) 13.4 13.9 12.0 12.0Normalized net profit margin, % 12.8% 14.5% 12.0% 13.4%  Enclosed: AB KN Energies 2025 Management Report together with the consolidated and separate financial statements prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The Management Report...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.